Stock of Centocor Inc. has jumped 40 percent since a Food andDrug Administration advisory panel recommended approval ofCentocor's septic shock product on Sept. 4.

The stock (NASDAQ:CNTO) closed up $5.75 at $52.50 onThursday, further spurred by positive comments made byOppenheimer & Co. analyst Jeffrey Casdin after the market'sclose on Wednesday to Oppenheimer's national retail andinstitutional sales forces.

Genetics Institute Inc. (NASDAQ:GENI) rose $3.25 to $38 afterCowen & Co. analyst David Stone reiterated his "buy" rating.Stone predicted that GI will move into the black in the thirdquarter, with earnings of between 5 cents and 15 cents pershare.

Stone also said that the European patent on granulocytemacrophage colony stimulating factor granted this week toSandoz Ltd., GI's licensee, "underscores what will be theirdominant patent position worldwide." Stone said he expectedU.S. and European marketing approvals for GM-CSF as early asthe first quarter of 1992.

Collagen Corp. stock (NASDAQ:CGEN) bucked Thursday's risingmarket, closing down $2.75 at $14.50 following a hearing ofthe House Energy and Commerce oversight and investigationssubcommittee.

Food and Drug Administration Commissioner Dr. David Kesslertold the hearing that he is considering submitting the issue ofwhether there is an association between injectable collagenand two rare autoimmune diseases to a scientific panel forpeer review, according to James McKinley, Collagen's chieffinancial officer.

McKinley said that Kessler also suggested that the Centers forDisease Control begin a new study of collagen. -- KB

(c) 1997 American Health Consultants. All rights reserved.